Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 A.m. ET.
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 A.m. ET.
Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease –
– 領先的醫學專家將討論在LDL-膽固醇管理中預防心血管疾病的持續未滿足需求 –
ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe).
美國密歇根州安娜堡，2025年1月9日（環球新聞）——Esperion（納斯達克：ESPR）今天宣佈將舉辦一次虛擬關鍵意見領袖（KOL）活動，討論NEXLETOL（bempedoic酸）和NEXLIZEt（bempedoic酸與依折麥布）的實際使用情況。
The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:
該活動將由Esperion臨牀開發負責人LeAnne Bloedon擔任主持，並將有以下討論：
-
Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center.
- Patrick Moriarty萬.D.，堪薩斯大學醫療中心醫學教授，堪薩斯州堪薩斯城，動脈粥樣硬化與脂質析出中心的臨牀藥理學主任。
Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
KOL網絡研討會的註冊可以在此處找到。可以通過Esperion網站的投資者和媒體部分訪問現場音頻網絡廣播。回放訪問將在通話完成後大約兩小時後提供，並將在公司的官方網站上存檔約90天。
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion Therapeutics
Esperion Therapeutics, Inc.是一家商業階段的生物製藥公司，專注於推出滿足患者和醫療專業人員未滿足需求的新藥。該公司開發並商業化了唯一獲得美國食品和藥物管理局（FDA）批准的口服，每日一次，非他汀類藥物，適用於有心血管疾病風險並且低密度脂蛋白膽固醇（LDL-C）升高的患者。這些藥物得到了近14,000名患者參與的CLEAR心血管結果試驗的支持。Esperion繼續在其下一代方案上取得成功，專注於開發ATP檸檬酸裂解酶抑制劑（ACLYi）。對ACLYi的結構和功能的新見解充分支持合理的藥物設計，併爲開發具有異構機制的高效特異性抑制劑提供了機會。
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion通過商業執行、國際合作夥伴關係與合作以及其臨牀前管道的推進，繼續發展成爲一家領先的全球生物製藥公司。更多信息，請訪問esperion.com和esperionscience.com，並在LinkedIn和X上關注Esperion。
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Esperion 聯繫信息：
投資者：
阿麗娜·****斯
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
媒體：
蒂芙尼·奧爾德里奇
corporateteam@esperion.com
(616) 443-8438
譯文內容由第三人軟體翻譯。
